Aesthetic Medicine Procedures in Oncology Patients: A Safety‐Based Clinical Framework for Restorative Oncodermatology
Dermatologic Therapy · 2026-01 · 2026 (1)
DOI: 10.1155/dth/5221506 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 18.10.2026. Verfasst von Lidia Majewska und 2 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Increasing survival rates in oncology and the transformation of many cancers into chronic diseases have created new challenges for aesthetic medicine. Dermatological sequelae of anticancer therapies—including volume loss, post‐surgical scarring, radiation‐induced telangiectasias and pigmentation disorders—significantly impair quality of life and body image. The immunological specificity of oncology patients, however, requires a substantially modified approach to aesthetic interventions, as articulated within the supportive and restorative oncodermatology frameworks.
Objective
To present a structured, literature‐based framework for the safe application of aesthetic medicine procedures in oncology patients, integrating immunological and clinical data with the principles of supportive oncodermatology.
Methods
Narrative review of clinical and immunological literature combined with expert synthesis. Procedures are stratified by safety profile for two patient populations: those undergoing active oncological treatment and long‐term survivors.
Results
Botulinum toxin, hyaluronic acid skin boosters, platelet‐rich plasma (PRP), photobiomodulation (PBM) and nonablative laser techniques represent the lowest‐risk interventions in this population. Immune checkpoint inhibitor (ICI) therapy substantially increases the risk of delayed granulomatous reactions at filler injection sites; emerging evidence further implicates BRAF and other tyrosine kinase inhibitors in late inflammatory filler reactions. Ablative lasers, deep chemical peels and permanent fillers require deferral or are absolutely contraindicated. We propose a qualification approach based on “red flags” (absolute neutrophil count, platelet count, active infection, immunotherapy status and radiotherapy timing).
Conclusions
Restorative oncodermatology, conceived within the broader supportive oncodermatology framework, treats aesthetic interventions not as luxury procedures but as a potential component of survivorship care. Standardized patient qualification, interdisciplinary collaboration with oncologists, and evidence‐informed procedure selection are essential. Given the limited prospective data, all recommendations presented here should be interpreted as the authors’ suggestions derived from the current literature and require individualized clinical judgment.
Zitieren
APA
Majewska, L., Dorosz, K., & Kijowski, J. (2026). Aesthetic Medicine Procedures in Oncology Patients: A Safety‐Based Clinical Framework for Restorative Oncodermatology. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/5221506
Vancouver
Majewska L, Dorosz K, Kijowski J. Aesthetic Medicine Procedures in Oncology Patients: A Safety‐Based Clinical Framework for Restorative Oncodermatology. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/5221506
BibTeX
@article{Majewska2026,
author = {Majewska, Lidia and Dorosz, Karolina and Kijowski, Jacek},
title = {Aesthetic Medicine Procedures in Oncology Patients: A Safety‐Based Clinical Framework for Restorative Oncodermatology},
journal = {Dermatologic Therapy},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/dth/5221506}
}
EUVIMED